Effects of Oral Cimetidine on Parathyroid Hormone and Calcitonin Plasma Levels in Uremic Patients
Reports concerning the effects of Cimetidine on parathyroid hormone levels in primary hyperparathyroidism (1–4) and in secondary hyperparathyroidism of renal failure (5–8) are increasing in number, but lead to disagreeing conclusions. These discrepancies are unclear and could be possibly explained by: 1) a variable compliance to treatment, since no measurement of plasma levels of Cimetidine has been made in these reports, 2) differences in specificity of parathyroid hormone immunoassays, since, in a studied group of hemodialysed patients, the lowering effect of Cimetidine on parathyroid hormone levels previously observed using a carboxyterminal antiserum (5), was not confirmed when the same samples were assayed a second time using an aminoterminal antiserum (9). It has also been suggested (8) that Cimetidine could act on the metabolic fate of circulating parathyroid hormone rather than on its secretion, thus explaining differences between results derived from either carboxy or aminoterminal immunoassays.
KeywordsParathyroid Hormone Primary Hyperparathyroidism Uremic Patient Renal Osteodystrophy Parathyroid Hormone Level
Unable to display preview. Download preview PDF.
- 2.F.J. Palmer, T.M. Sawyers, S.J. Wierzbinski. Cimetidine and hyperparathyroidism. Lancet i: 692 (1980).Google Scholar
- 5.A.I. Jacob, D.Jr. Lanier, J. Canterbury, J.J. Bourgoignie. Reduction by Cimetidine of serum parathyroid hormone levels in uremic patients. N. Engl. J. Med. 302: 671 (1980).Google Scholar
- 6.C.J. Beehler, J.R. Beckner, C. Rosenquist, S.W. Shankel. Parathyroid hormone suppression by Cimetidine in the uremic patients. Ann. Inter. Med. 93: 840 (1980).Google Scholar
- 10.J.A. Kanis, M. Earnshaw, G. Heynen, J.G.G. Ledingham, D.O. Oliver, G.G. Russell, C.G. Woods, P. Franchimont, S. Gaspar. Changes in histologic and biochemical indexes of bone turnover after bilateral nephrectomy in patients on hemodialysis. Evidence for a possible role of endogenous calcitonin. N. Engl. J. Med. 296: 1073 (1977).PubMedCrossRefGoogle Scholar
- 13.J.L. Sebert, A. Fournier, J. Gueris, G. Lambrey, J.F. de Fremont, P. Marie, R. Makdassi, A. Smadja, A. Marie, D. Kuntz, A. Ryckewaert, J. Quichaud, P.J. Meunier. Limit by hyperphosphatemia of the usefulness of vitamin D metabolites (1 — hydroxycholecalciferol and 25 hydroxycholecalciferol) in the treatment of renal osteodystrophy. Metab. Bone. Dis. and Rel. Res. 2: 217 (1980).CrossRefGoogle Scholar
- 14.P.L. Vigo, E.E. Polli, G. Milhaud, M.S. Moukhtar, C. Desplan, J. Duriez. Aminoterminal parathyroid hormone radioimmunoassay to evaluate bone status in renal failure. Lancet i: 443 (1981).Google Scholar
- 15.M.S. Moukhtar, A. Jullienne, P. Rivaille, G. Milhaud. Dosage radioimmunologique de la calcitonine humaine. Etude immunochimique et comparaison avec le dosage biologique. In: Radioimmunoassay and related procedures in clinical medicine and research p. 381, International Atomic Energy Agency, Vienna (1973).Google Scholar
- 21.R.S. Longley, G.K. Hargis, E.N. Bowser, S.C. Kukreja, P.A. Johnson, B.L. Jackson, W.J. Kawahara, G.A. Williams. Parathyroid hormone and calcitonin secretion: role of histamine H2 receptors. Clin. Res. 28: 398 A (1980).Google Scholar